<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35156226</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2990</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>48</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neuropathology and applied neurobiology</Title>
          <ISOAbbreviation>Neuropathol Appl Neurobiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>CD47 promotes the proliferation and migration of adamantinomatous craniopharyngioma cells by activating the MAPK/ERK pathway, and CD47 blockade facilitates microglia-mediated phagocytosis.</ArticleTitle>
        <Pagination>
          <StartPage>e12795</StartPage>
          <MedlinePgn>e12795</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/nan.12795</ELocationID>
        <Abstract>
          <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">CD47 is overexpressed in multiple tumours and plays an important role in immune escape and other biological processes of tumours. However, its role in adamantinomatous craniopharyngioma (ACP) remains unclear. Therefore, we explored the functions of CD47 in ACP.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">In this study, the expression of CD47 and the infiltration of immune cells in ACP was determined by immunohistochemistry (IHC) or immunofluorescence. Microglia-mediated phagocytosis was analysed using an in vitro phagocytosis assay. Using lentivirus transfection, CD47 was either silenced or overexpressed in primary ACP cells and the biological effects of CD47 on these cells were evaluated in vitro using cell viability, flow cytometry, wound healing, Transwell migration and 3D hydrogel assays. The protein expression levels were analysed by western blotting.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Finger-like protrusions, which may be the key factor in the recurrence of ACP, were primarily found in the region of hypothalamic involvement. The expression of CD47 was higher in palisading epithelium compared with stellate reticulum and epithelial whorls. An in vitro phagocytosis assay showed that CD47 blockade could promote microglia-mediated phagocytosis. Functional assays revealed that CD47 promoted the growth, migration and invasion of ACP cells in vitro. Our mechanistic investigations showed that CD47 activated the MAPK/ERK pathway, thereby facilitating the biological behaviour of ACP cells.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Here, we demonstrated that CD47 plays an important role in ACP cells, suggesting that CD47 could be a new potential therapeutic target for ACP, and adding to the body of literature a role for the inhibition of MAPK/ERK in ACP.</AbstractText>
          <CopyrightInformation>Â© 2022 British Neuropathological Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Huarong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Chaohu</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fan</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Qianchao</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Yiwen</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peng</LastName>
            <ForeName>Junxiang</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Jin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Songtao</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Neuropathol Appl Neurobiol</MedlineTA>
        <NlmUniqueID>7609829</NlmUniqueID>
        <ISSNLinking>0305-1846</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051928">CD47 Antigen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497894">CD47 protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D051928" MajorTopicYN="N">CD47 Antigen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003397" MajorTopicYN="Y">Craniopharyngioma</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="N">MAP Kinase Signaling System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010587" MajorTopicYN="N">Phagocytosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010911" MajorTopicYN="Y">Pituitary Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CD47</Keyword>
        <Keyword MajorTopicYN="N">MAPK/ERK pathway</Keyword>
        <Keyword MajorTopicYN="N">adamantinomatous craniopharyngioma</Keyword>
        <Keyword MajorTopicYN="N">microglia-mediated phagocytosis</Keyword>
        <Keyword MajorTopicYN="N">migration</Keyword>
        <Keyword MajorTopicYN="N">palisading epithelium</Keyword>
        <Keyword MajorTopicYN="N">proliferation</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>14</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35156226</ArticleId>
        <ArticleId IdType="doi">10.1111/nan.12795</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Bishokarma S, Shrestha S, Ranabhat K, et al. Outcome of surgical resection of craniopharyngioma: single center 12 years' experience. Kathmandu Univ Med J (KUMJ). 2018;16(64):328-332.</Citation>
        </Reference>
        <Reference>
          <Citation>Varlotto J, DiMaio C, Grassberger C, et al. Multi-modality management of craniopharyngioma: a review of various treatments and their outcomes. Neuro-Oncology Practice. 2016;3(3):173-187. doi:10.1093/nop/npv029</Citation>
        </Reference>
        <Reference>
          <Citation>KiliÃ§ M, Can SM, Ãzdemir B, Tanik C. Management of craniopharyngioma. J Craniofac Surg. 2019;30(2):e178-e183. doi:10.1097/SCS.0000000000005136</Citation>
        </Reference>
        <Reference>
          <Citation>Dandurand C, Sepehry AA, Asadi Lari MH, Akagami R, Gooderham P. Adult craniopharyngioma: case series, systematic review, and meta-analysis. Neurosurgery. 2018;83(4):631-641. doi:10.1093/neuros/nyx570</Citation>
        </Reference>
        <Reference>
          <Citation>MÃ¼ller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S. Craniopharyngioma. Nat Rev Dis Primers. 2019;5(1):75. doi:10.1038/s41572-019-0125-9</Citation>
        </Reference>
        <Reference>
          <Citation>Elowe-Gruau E, Beltrand J, Brauner R, et al. Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab. 2013;98(6):2376-2382. doi:10.1210/jc.2012-3928</Citation>
        </Reference>
        <Reference>
          <Citation>Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133-150. doi:10.1038/s41568-019-0116-x</Citation>
        </Reference>
        <Reference>
          <Citation>Lian S, Xie R, Ye Y, et al. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. EBioMedicine. 2019;42:281-295. doi:10.1016/j.ebiom.2019.03.018</Citation>
        </Reference>
        <Reference>
          <Citation>Lu Y, Liang H, Yu T, et al. Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry. Cancer. 2015;121(17):3036-3045. doi:10.1002/cncr.29444</Citation>
        </Reference>
        <Reference>
          <Citation>Anderson KL, Snyder KM, Ito D, et al. Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade. Melanoma Res. 2020;30(2):147-158. doi:10.1097/CMR.0000000000000629</Citation>
        </Reference>
        <Reference>
          <Citation>Lian S, Xie X, Lu Y, Jia L. Checkpoint CD47 function on tumor metastasis and immune therapy. Onco Targets Ther. 2019;12:9105-9114. doi:10.2147/OTT.S220196</Citation>
        </Reference>
        <Reference>
          <Citation>Murata Y, Kotani T, Ohnishi H, Matozaki T. The CD47-SIRP signalling system: its physiological roles and therapeutic application. J Biochem. 2014;155(6):335-344. doi:10.1093/jb/mvu017</Citation>
        </Reference>
        <Reference>
          <Citation>Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 2011;118(18):4890-4901. doi:10.1182/blood-2011-02-338020</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao H, Wang J, Kong X, et al. CD47 promotes tumor invasion and metastasis in non-small cell lung cancer. Sci Rep. 2016;6(1): doi:10.1038/srep29719</Citation>
        </Reference>
        <Reference>
          <Citation>Hu T, Liu H, Liang Z, et al. Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis. Theranostics. 2020;10(9):4056-4072. doi:10.7150/thno.40860</Citation>
        </Reference>
        <Reference>
          <Citation>Hanke JH, Gardner JP, Dow RL, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem. 1996;271(2):695-701. doi:10.1074/jbc.271.2.695</Citation>
        </Reference>
        <Reference>
          <Citation>Shinohara M, Ohyama N, Murata Y, et al. CD47 regulation of epithelial cell spreading and migration, and its signal transduction. Cancer Sci. 2006;97(9):889-895. doi:10.1111/j.1349-7006.2006.00245.x</Citation>
        </Reference>
        <Reference>
          <Citation>Li H, Wang Y, Li YZ. MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47. Tumour Biol. 2016;37(12):16103-16113. doi:10.1007/s13277-016-5451-x</Citation>
        </Reference>
        <Reference>
          <Citation>Sick E, Boukhari A, Deramaudt T, et al. Activation of CD47 receptors causes proliferation of human astrocytoma but not normal astrocytes via an Akt-dependent pathway. Glia. 2011;59(2):308-319. doi:10.1002/glia.21102</Citation>
        </Reference>
        <Reference>
          <Citation>Congote LF, Temmel N. The C-terminal 26-residue peptide of serpin A1 stimulates proliferation of breast and liver cancer cells: role of protein kinase C and CD47. FEBS Lett. 2004;576(3):343-347. doi:10.1016/j.febslet.2004.09.035</Citation>
        </Reference>
        <Reference>
          <Citation>Wu J, Wu X, Yang YQ, et al. Association of histological subtype with risk of recurrence in craniopharyngioma patients: a systematic review and meta-analysis. Neurosurg Rev. 2021;45(1):139-150. doi:10.1007/s10143-021-01563-9</Citation>
        </Reference>
        <Reference>
          <Citation>Burghaus S, Holsken A, Buchfelder M, et al. A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch. 2010;456(3):287-300. doi:10.1007/s00428-009-0873-0</Citation>
        </Reference>
        <Reference>
          <Citation>Prieto R, Castro-Dufourny I, Carrasco R, Barrios L, Pascual JM. Craniopharyngioma recurrence: the impact of tumor topography. J Neurosurg. 2016;125(4):1043-1049. doi:10.3171/2016.3.JNS16630</Citation>
        </Reference>
        <Reference>
          <Citation>Asha MJ, Oswari S, Takami H, Velasquez C, Almeida JP, Gentili F. Craniopharyngiomas: challenges and controversies. World Neurosurg. 2020;142:593-600. doi:10.1016/j.wneu.2020.05.172</Citation>
        </Reference>
        <Reference>
          <Citation>Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol. 2010;7(3):153-162. doi:10.1038/nrclinonc.2009.237</Citation>
        </Reference>
        <Reference>
          <Citation>Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413. doi:10.1126/science.aan6733</Citation>
        </Reference>
        <Reference>
          <Citation>Kojima Y, Volkmer J-P, McKenna K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536(7614):86-90. doi:10.1038/nature18935</Citation>
        </Reference>
        <Reference>
          <Citation>Wang B, Liu T, Wu J-C, et al. STAT3 aggravates TGF-Î²1-induced hepatic epithelial-to-mesenchymal transition and migration. Biomed Pharmacother. 2018;98:214-221. doi:10.1016/j.biopha.2017.12.035</Citation>
        </Reference>
        <Reference>
          <Citation>Miller TW, Ren W, Liu Y, et al. BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways. PLoS ONE. 2014;9(5): doi:10.1371/journal.pone.0096816</Citation>
        </Reference>
        <Reference>
          <Citation>Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109. doi:10.1007/s00401-007-0243-4</Citation>
        </Reference>
        <Reference>
          <Citation>Weiner HL, Wisoff JH, Rosenberg ME, et al. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery. 1994;35(6):1001-1010. doi:10.1097/00006123-199412000-00001</Citation>
        </Reference>
        <Reference>
          <Citation>Crotty TB, Scheithauer BW, Young WF Jr, et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg. 1995;83(2):206-214. doi:10.3171/jns.1995.83.2.0206</Citation>
        </Reference>
        <Reference>
          <Citation>Hirano A, Wate R. Diagnostic clues and more from photographs. Neuropathology. 2007;27(1):1-9. doi:10.1111/j.1440-1789.2006.00764.x</Citation>
        </Reference>
        <Reference>
          <Citation>Moussa AH, Kerasha AA, Mahmoud ME. Surprising outcome of ommaya reservoir in treating cystic craniopharyngioma: a retrospective study. Br J Neurosurg. 2013;27(3):370-373. doi:10.3109/02688697.2012.741732</Citation>
        </Reference>
        <Reference>
          <Citation>Apps JR, Hutchinson JC, Arthurs OJ, et al. Imaging Invasion: micro-CT imaging of adamantinomatous craniopharyngioma highlights cell type specific spatial relationships of tissue invasion. Acta Neuropathol Commun. 2016;4(1):57 doi:10.1186/s40478-016-0321-8</Citation>
        </Reference>
        <Reference>
          <Citation>Qi S, Liu Y, Wang C, et al. Membrane structures between craniopharyngioma and the third ventricle floor based on the QST classification and its significance: a pathological study. J Neuropathol Exp Neurol. 2020;79(9):966-974. doi:10.1093/jnen/nlaa087</Citation>
        </Reference>
        <Reference>
          <Citation>Liu Y, Qi ST, Wang CH, et al. Pathological relationship between adamantinomatous craniopharyngioma and adjacent structures based on QST classification. J Neuropathol Exp Neurol. 2018;77(11):1017-1023. doi:10.1093/jnen/nly083</Citation>
        </Reference>
        <Reference>
          <Citation>Brastianos PK, Shankar GM, Gill CM, et al. Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst. 2016;108(2):djv310 doi:10.1093/jnci/djv310</Citation>
        </Reference>
        <Reference>
          <Citation>Roque A, Odia Y. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. CNS Oncol. 2017;6(2):95-99. doi:10.2217/cns-2016-0034</Citation>
        </Reference>
        <Reference>
          <Citation>Himes BT, Ruff MW, Van Gompel JJ, et al. Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. J Neurosurg. 2018;1-5(S 01):S1-S188. doi:10.1055/s-0038-1633655</Citation>
        </Reference>
        <Reference>
          <Citation>Juratli TA, Jones PS, Wang N, et al. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. Cancer. 2019;125(17):2910-2914. doi:10.1002/cncr.32197</Citation>
        </Reference>
        <Reference>
          <Citation>Apps JR, Carreno G, Gonzalez-Meljem JM, et al. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. Acta Neuropathol. 2018;135(5):757-777. doi:10.1007/s00401-018-1830-2</Citation>
        </Reference>
        <Reference>
          <Citation>Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325-340. doi:10.1038/nrclinonc.2018.29</Citation>
        </Reference>
        <Reference>
          <Citation>Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477): doi:10.1126/science.aax0182</Citation>
        </Reference>
        <Reference>
          <Citation>Hacking S, Chavarria H, Jin C, Perry A, Nasim M. Landscape of immune checkpoint inhibition in carcinosarcoma (MMMT): analysis of IDO-1, PD-L1 and PD-1. Pathology - Research and Practice. 2020;216(4):152847 doi:10.1016/j.prp.2020.152847</Citation>
        </Reference>
        <Reference>
          <Citation>Coy S, Rashid R, Lin JR, et al. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro Oncol. 2018;20(8):1101-1112. doi:10.1093/neuonc/noy035</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Y, Deng J, Wang L, et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma. J Immunother Cancer. 2020;8(2):e000406 doi:10.1136/jitc-2019-000406</Citation>
        </Reference>
        <Reference>
          <Citation>Eso Y, Shimizu T, Takeda H, Takai A, Marusawa H. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol. 2019;55(1):15-26. doi:10.1007/s00535-019-01620-7</Citation>
        </Reference>
        <Reference>
          <Citation>Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncology. 2015;1(9):1319-1323. doi:10.1001/jamaoncol.2015.2151</Citation>
        </Reference>
        <Reference>
          <Citation>Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma. New England Journal of Medicine. 2018;379(18):1711-1721. doi:10.1056/NEJMoa1807315</Citation>
        </Reference>
        <Reference>
          <Citation>Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci. 2012;109(17):6662-6667. doi:10.1073/pnas.1121623109</Citation>
        </Reference>
        <Reference>
          <Citation>Veillette A, Chen J. SIRPÎ±-CD47 immune checkpoint blockade in anticancer therapy. Trends Immunol. 2018;39(3):173-184. doi:10.1016/j.it.2017.12.005</Citation>
        </Reference>
        <Reference>
          <Citation>Liu X, Pu Y, Cron K, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21(10):1209-1215. doi:10.1038/nm.3931</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang X, Wang S, Nan Y, et al. Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma. Appl Microbiol Biotechnol. 2018;102(15):6503-6513. doi:10.1007/s00253-018-9069-3</Citation>
        </Reference>
        <Reference>
          <Citation>Kamijo H, Miyagaki T, Takahashi-Shishido N, et al. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47. Leukemia. 2019;34(3):845-856. doi:10.1038/s41375-019-0622-6</Citation>
        </Reference>
        <Reference>
          <Citation>Kaur S, Elkahloun AG, Singh SP, et al. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. Oncotarget. 2016;7(9):10133-10152. doi:10.18632/oncotarget.7100</Citation>
        </Reference>
        <Reference>
          <Citation>Martin-Orozco E, Sanchez-Fernandez A, Ortiz-Parra I, Ayala-San NM. WNT signaling in tumors: the way to evade drugs and immunity. Front Immunol. 2019;10: doi:10.3389/fimmu.2019.02854</Citation>
        </Reference>
        <Reference>
          <Citation>Holsken A, Gebhardt M, Buchfelder M, Fahlbusch R, Blumcke I, Buslei R. EGFR signaling regulates tumor cell migration in craniopharyngiomas. Clin Cancer Res. 2011;17(13):4367-4377. doi:10.1158/1078-0432.CCR-10-2811</Citation>
        </Reference>
        <Reference>
          <Citation>Gantner CW, Hunt CPJ, Niclis JC, et al. FGF-MAPK signaling regulates human deep-layer corticogenesis. Stem Cell Reports. 2021;16(5):1262-1275. doi:10.1016/j.stemcr.2021.03.014</Citation>
        </Reference>
        <Reference>
          <Citation>Ramos C, Becerril C, MontaÃ±o M, et al. FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol. 2010;299(2):L222-L231. doi:10.1152/ajplung.00070.2010</Citation>
        </Reference>
        <Reference>
          <Citation>Gros J, Hu JK, Vinegoni C, Feruglio PF, Weissleder R, Tabin CJ. WNT5A/JNK and FGF/MAPK pathways regulate the cellular events shaping the vertebrate limb bud. Curr Biol. 2010;20(22):1993-2002. doi:10.1016/j.cub.2010.09.063</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
